In many large trials, reducing low density lipoprotein (LDL) levels with rosuvastatin
decreased the incidence of major cardiovascular events，but little attention to the effects of
rosuvastatin on HDL level，especially on HDL subtype.
Epidemiological evidence strongly favors the notion that the risk of cardiovascular disease
(CVD) is inversely related to the plasma high-density lipoprotein (HDL) cholesterol
concentration.
HDL can be subdivided into large-sized (HDL2a, HDL2b) and small-sized subclasses (preb1-HDL,
HDL3c, HDL3b, HDL3a) and preb2-HDL. Some studies indicate that only large HDL2a and HDL2b
particles make HDLs possess anti-atherogenic functions.
The investigators assume that rosuvastatin could play the role of anti-atherosclerosis though
the levels of HDL2a、HDL2b increased.
Phase:
Phase 4
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University